The investment will accelerate the delivery of tests addressing kidney function and cardiac risk expected to gain U.S. Food and Drug Administration 510(k) approval early next year, according to the announcement.
WHY IT MATTERS
Using algorithms to analyze multiple biomarkers to measure disease…
From: www.healthcareitnews.com – Read more
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
